Dropped drugs cast shadow over Merck KGaA 1Q growth
This article was originally published in Scrip
Executive Summary
Merck KGaA reported relatively healthy first-quarter earnings on 14 May, with moderate revenue and sales growth across the group and double-digit earnings per share growth.
You may also be interested in...
Almirall launches Constella in six European markets
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira raises $35m in series B
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis ups public offering to $240m
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.